Eduovisual
Cardiovascular
Abdominal aortic aneurysm: USPSTF screening and repair indications
— Most AAAs are infrarenal (~90%); juxtarenal/suprarenal variants alter repair strategy.
— Pathology is degenerative with elastin/collagen breakdown, MMP activity, and chronic inflammation — not classic "atherosclerosis" alone, though risk factors overlap heavily.
— Men ≥65, ever-smokers (single strongest modifiable risk factor), white race, family history of AAA in a first-degree relative.
— HTN, hyperlipidemia, COPD, and CAD frequently coexist.
— Protective factors: female sex, Black/Hispanic race, diabetes mellitus (yes — DM is paradoxically protective against AAA growth).
— Asymptomatic older male smoker noted to have a "pulsatile abdominal mass" on routine exam → screen/confirm with ultrasound.
— Triad of hypotension + abdominal/back pain + pulsatile mass = ruptured AAA until proven otherwise; do not delay for imaging if unstable.
— Atypical presentations: flank pain mimicking renal colic in an older smoker, syncope, or new lower-extremity emboli ("blue toe syndrome").
— ~4–8% prevalence in older male smokers; rupture mortality approaches 80–90% overall and ~50% even after emergent repair.
— AAA accounts for ~10,000 US deaths/year; mortality has fallen with screening + endovascular repair.
Board pearl: On Step 3, any older male ever-smoker with vague abdominal/back pain deserves an AAA on your differential — screening is preventive medicine's highest-yield AAA question, and rupture is the highest-yield emergency presentation. Diabetes being protective is a frequent distractor-flip in vignettes.
— Discovered incidentally on imaging done for another reason (CT for renal stone, lumbar MRI, abdominal US for gallstones) or via USPSTF screening.
— Step 3 stem clue: "65-year-old man, 30 pack-years, here for Medicare wellness visit."
— Vague gnawing abdominal, flank, or low back pain — often mistaken for musculoskeletal or GU pathology.
— Early satiety or weight loss from mass effect on duodenum.
— Embolic phenomena: livedo reticularis, blue toe syndrome, or acute limb ischemia from mural thrombus showering distally.
— Classic triad: sudden severe abdominal or back pain + hypotension + pulsatile mass (present in only ~50%, so absence does not exclude).
— "Herald bleed" — transient hypotension that resolves with fluids, followed by catastrophic re-rupture.
— Retroperitoneal rupture → flank ecchymosis (Grey Turner) or periumbilical ecchymosis (Cullen), syncope, anuria.
— Aortoenteric fistula: sentinel upper or lower GI bleed in a patient with prior open AAA repair → massive hemorrhage if missed; CT angiography urgently.
— Aortocaval fistula: high-output heart failure, machinery abdominal bruit, lower-extremity edema, hematuria.
— Smoking pack-years and quit date; family history of AAA (doubles risk); prior vascular disease; connective tissue disorders (Marfan, Ehlers-Danlos type IV, Loeys-Dietz) suggest thoracic involvement too.
— Medication review for anticoagulation (alters rupture-risk discussion) and prior fluoroquinolone exposure (associated with aneurysm growth/dissection — FDA warning).
Key distinction: Ruptured AAA classically presents as "renal colic in an older smoker who has never had a stone before." Always image the aorta — not just the kidneys — when the demographic doesn't fit nephrolithiasis. This flip is a perennial Step 3 trap.
— Palpate above the umbilicus with both hands; a pulsatile, expansile mass widening laterally suggests AAA.
— Sensitivity of palpation is poor (~30% for 3–4 cm, ~75% for ≥5 cm) and decreases with obesity — a negative exam does not rule out AAA.
— Auscultate for abdominal bruits (suggest associated renal/mesenteric stenosis but not specific).
— Document femoral, popliteal, dorsalis pedis, posterior tibial pulses bilaterally; popliteal aneurysms coexist in ~10% of AAA patients (and vice versa, ~30–50%).
— Look for distal embolic stigmata: blue toes, splinter hemorrhages, livedo reticularis.
— Permissive hypotension: target SBP ~70–90 mmHg or mental status/urine output as proxy — aggressive resuscitation worsens bleeding by disrupting tamponade clot.
— Two large-bore IVs, type & crossmatch for ≥6 units PRBCs, activate massive transfusion protocol (1:1:1 PRBC:FFP:platelets).
— Avoid over-resuscitation before proximal aortic control is achieved.
— Narrowing pulse pressure, tachycardia, cool extremities, confusion, oliguria.
— Flank/periumbilical ecchymosis appears late (12–24 h) and indicates retroperitoneal blood.
— Free intraperitoneal fluid is rare in AAA rupture (most are retroperitoneal); aortic measurement >5 cm with appropriate symptoms = rupture until proven otherwise.
CCS pearl: In a CCS case of suspected ruptured AAA, your first orders are simultaneously: large-bore IV access, T&C 6 units, activate MTP, vascular surgery STAT consult, and either OR transfer (unstable) or CT angiography (stable). Do not order excessive crystalloid — permissive hypotension is the modern standard.
— Gold standard for screening because it is inexpensive, no radiation, no contrast, and ~95–100% sensitive/specific for infrarenal AAA.
— Measure outer-to-outer wall in AP diameter; ≥3.0 cm defines AAA.
— Does not reliably assess rupture, suprarenal extension, or surgical planning details.
— Men 65–75 who have ever smoked (≥100 cigarettes lifetime): Grade B — one-time screening US.
— Men 65–75 who never smoked: Grade C — selectively offer (e.g., family history, other vascular disease).
— Women 65–75 who ever smoked: Grade I (insufficient evidence).
— Women who never smoked: Grade D — do not screen.
— Society of Vascular Surgery extends screening to women 65–75 who smoked or have family history — be aware but USPSTF is the Step 3 answer.
— CBC, BMP (baseline creatinine before contrast), coagulation studies, type & screen/cross, lipid panel, HbA1c, troponin if cardiac concern.
— Urinalysis to exclude alternate diagnoses (e.g., nephrolithiasis, UTI).
Step 3 management: A 70-year-old man with a 20-pack-year history at his wellness visit who has never been screened gets a one-time abdominal ultrasound, not CT. Document the screening, the result, and the surveillance interval. If the patient is 76+ and never screened, screening is generally not recommended — life expectancy and procedure risk dominate.
— Modality of choice for surgical planning, suspected rupture in stable patients, and characterizing aneurysm anatomy (neck length/angulation, iliac involvement, suprarenal extension, mural thrombus, accessory renal arteries).
— Required before EVAR to assess endograft suitability.
— In unstable suspected rupture: skip CT, go directly to OR if surgeon is willing — clinical diagnosis suffices.
— Alternative in patients with contrast allergy or CKD (gadolinium concerns with eGFR <30 — avoid or use cyclic agents); slower, less available in emergencies.
— Largely supplanted by CTA for diagnosis; reserved for intraoperative use during endovascular repair.
— 3.0–3.9 cm: every 3 years
— 4.0–4.9 cm: every 12 months
— 5.0–5.4 cm: every 6 months
— ≥5.5 cm (men) or ≥5.0 cm (women): refer for repair evaluation
— Rapid expansion ≥0.5 cm/6 months or ≥1 cm/year: refer regardless of size.
— AAA repair is an elevated-risk surgery (vascular). Apply ACC/AHA stepwise algorithm: functional capacity ≥4 METs → proceed; <4 METs or unknown with active cardiac conditions → stress testing only if it will change management.
— Optimize beta-blockers if already on them; do not initiate high-dose beta-blockade on day of surgery (POISE trial harm).
Board pearl: The single most testable surveillance fact: men ≥5.5 cm or women ≥5.0 cm = repair indication. Rapid expansion or symptoms lower that threshold. Women rupture at smaller diameters, hence the lower female threshold.
— Size: ≥5.5 cm in men, ≥5.0 cm in women.
— Rapid expansion: ≥0.5 cm in 6 months or ≥1.0 cm in 1 year.
— Symptomatic AAA of any size (abdominal/back pain attributable to aneurysm, distal embolization, tenderness on palpation) — bridges to urgent rather than emergent repair.
— <4.0 cm: <0.5%
— 4.0–4.9 cm: ~1%
— 5.0–5.9 cm: ~3–15%
— 6.0–6.9 cm: ~10–20%
— ≥7.0 cm: ~30–50%
— These numbers underpin why 5.5 cm is the operative threshold — risk of rupture begins to exceed perioperative mortality (~3–5% open, ~1–2% EVAR).
— Surveillance imaging at intervals above.
— Aggressive risk factor modification is the cornerstone — see chunk 7.
— No evidence that medications shrink AAAs; goal is to slow growth and reduce cardiovascular mortality (the most common cause of death in AAA patients is MI, not rupture).
— Discuss life expectancy, comorbidities, operative risk, and patient preferences before recommending repair, especially at borderline thresholds.
— Frailty assessment (gait speed, Clinical Frailty Scale) informs candidacy.
Step 3 management: A 68-year-old man with a 4.2 cm AAA, smoker, HTN, LDL 140 → continue surveillance ultrasound annually, quit smoking, start statin and antihypertensive, control BP <130/80. Do not refer to vascular surgery yet. Tobacco cessation is the single most impactful intervention to slow AAA growth.
— Smoking accelerates AAA growth and rupture risk more than any other factor.
— Combine behavioral counseling with pharmacotherapy: varenicline (most effective monotherapy), bupropion, or nicotine replacement.
— Document cessation counseling at every visit (also a quality measure).
— Target <130/80 mmHg per current AHA/ACC guidelines in vascular disease.
— Preferred agents: ACE inhibitors or ARBs (renoprotective, cardioprotective in CAD), with beta-blockers added if CAD or post-MI.
— Beta-blockers were once thought to slow AAA growth — modern trials (PIVOTAL, others) show minimal AAA-specific benefit, but they remain valuable for coexisting CAD and perioperative cardiac protection in patients already on them.
— High-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) for all AAA patients — AAA is a coronary risk equivalent.
— Reduces all-cause and cardiovascular mortality, and may modestly slow aneurysm expansion.
— Low-dose aspirin (81 mg) for secondary prevention given high coexisting atherosclerotic burden — not for the AAA itself but for ASCVD risk.
— Not indicated as primary prevention in patients without other vascular disease.
— Control to individualized HbA1c target (~7%) — DM is associated with slower AAA growth but worse cardiovascular outcomes overall.
— Fluoroquinolones when alternatives exist — FDA black-box warning for aortic dissection/rupture in patients with aneurysms.
— Heavy isometric exertion in large aneurysms (relative).
Board pearl: No medication "treats" an AAA, but smoking cessation + statin + BP control + aspirin (if ASCVD) is the universal medical bundle. Avoid fluoroquinolones — a common Step 3 prescribing-error question.
— Stent graft deployed via femoral access; covers aneurysm sac from within.
— Lower 30-day mortality (~1–2%) and shorter hospital stay vs open repair.
— Long-term survival converges with open at ~3 years; EVAR has higher reintervention rate.
— Requires favorable anatomy: adequate proximal neck length (≥10–15 mm), limited angulation, suitable iliac access vessels.
— Midline laparotomy or retroperitoneal approach; aorta cross-clamped, graft sewn in.
— Higher perioperative mortality (~3–5%) and morbidity but more durable — fewer reinterventions.
— Preferred in younger, lower-risk patients, unfavorable EVAR anatomy, or connective tissue disease.
— Older, multiple comorbidities, favorable anatomy → EVAR.
— Young (<70), good operative candidate, hostile neck anatomy, or connective tissue disorder (Marfan) → open repair (EVAR fixation fails in CT disorders).
— Ruptured AAA: emergent EVAR if anatomy and resources allow (better outcomes than open in modern centers); otherwise emergent open.
— Endoleaks (most testable):
— Type I: leak at proximal/distal seal — requires reintervention.
— Type II: retrograde flow from lumbar/IMA branches — most common, often observed if sac stable.
— Type III: fabric tear or component separation — reintervention.
— Type IV: graft porosity — usually self-limited.
— Type V (endotension): sac growth without identifiable leak.
— Graft migration, limb occlusion, infection.
CCS pearl: Post-EVAR patients need lifelong imaging surveillance — do not discharge them from vascular follow-up. Open repair patients can transition to less intensive surveillance after the early post-op period.
— Life expectancy and frailty drive decision-making more than diameter alone.
— Stop screening after age 75 per USPSTF if not previously screened (limited evidence of benefit; competing mortality).
— If known AAA, continue surveillance only if patient would accept and tolerate repair — otherwise shift to palliative framing.
— EVAR is favored in elderly due to lower perioperative mortality, but contrast load and access vessel disease are limiting.
— CTA contrast nephropathy risk → pre-procedure hydration with isotonic saline, consider CO₂ angiography for EVAR planning if eGFR <30.
— Avoid gadolinium if eGFR <30 (NSF risk); use non-contrast MRA or duplex when feasible.
— EVAR contrast burden may precipitate need for renal replacement; weigh against open repair (which has its own renal ischemic risk from suprarenal clamp).
— Suprarenal clamp in open repair → higher AKI risk than infrarenal.
— Coagulopathy from cirrhosis dramatically increases bleeding risk in either approach.
— Child-Pugh C is a relative contraindication to elective open repair; EVAR preferred when anatomy allows.
— Ascites complicates wound healing post-open.
— Severe COPD, EF <30%, or recent MI shift toward EVAR or non-operative management.
— Multidisciplinary review (vascular surgery, cardiology, anesthesia) for high-risk candidates.
— Pre-op gait speed, ADL independence, and cognitive baseline predict 1-year outcomes better than age alone.
Step 3 management: An 82-year-old man with a 5.6 cm AAA, COPD on home O₂, CKD stage 4, and frailty → shared decision-making about EVAR vs conservative management with palliative orientation. Repair is not mandatory just because the threshold is met — frame benefit/burden honestly.
— Lower prevalence overall but higher rupture risk at smaller diameters — hence the 5.0 cm repair threshold (vs 5.5 cm in men).
— Worse perioperative outcomes for both EVAR and open repair (smaller, more tortuous access vessels; later presentation).
— USPSTF: insufficient evidence to screen ever-smokers (Grade I); do not screen never-smokers (Grade D). SVS suggests selective screening of women 65–75 with smoking or family history.
— First-degree relative with AAA roughly doubles risk; consider screening starting at age 55–60, and offer screening to siblings/children.
— Familial clustering is real even without identified syndromic disease.
— Marfan syndrome (FBN1): primarily thoracic aortic disease, but abdominal involvement occurs. Repair thresholds are lower (often 5.0 cm or rapid growth). Open repair preferred — EVAR fixation in friable tissue is unreliable.
— Loeys-Dietz, vascular Ehlers-Danlos (type IV, COL3A1): even more aggressive course; repair at smaller diameters; surgery is hazardous due to tissue fragility.
— Bicuspid aortic valve: thoracic association more than abdominal.
— ~5% of AAAs; thickened wall, periaortic fibrosis, often involves ureters (hydronephrosis).
— Associated with IgG4-related disease in subset.
— Symptoms more common (back pain, weight loss, elevated ESR/CRP).
— Repair indications are similar; perioperative steroids may be considered.
— True AAA in pregnancy is rare; if present, manage with maternal-fetal medicine + vascular surgery; rupture is catastrophic.
Key distinction: Marfan patient with AAA → open repair, not EVAR. The diseased aortic wall cannot reliably hold endograft anchors, and re-dissection at the seal zone is common. Same logic for Loeys-Dietz and vascular EDS.
— Free intraperitoneal rupture → exsanguination within minutes; overall mortality 80–90%.
— Contained retroperitoneal rupture allows a narrow window for repair; ~50% survive to discharge after emergent surgery.
— Mural thrombus showers debris → blue toe syndrome, acute limb ischemia, renal/mesenteric infarction.
— Treatment is repair of the aneurysm + supportive care for the ischemic territory.
— Primary (rare, untreated AAA erodes into duodenum) or secondary (after prior graft, more common).
— "Herald" GI bleed followed by massive hemorrhage; CTA or upper endoscopy; emergent surgery.
— Aneurysm erodes into IVC → high-output heart failure, machinery bruit, lower-extremity edema, hematuria.
— MI (leading cause of 30-day mortality), AKI (especially with suprarenal clamp), bowel ischemia (IMA ligation → colonic ischemia in 1–3%), spinal cord ischemia (rare, more with thoracoabdominal), graft infection, incisional hernia, sexual dysfunction.
— Endoleaks (see chunk 8), graft migration, limb thrombosis, post-implantation syndrome (fever, leukocytosis, elevated CRP, self-limited), access site complications (pseudoaneurysm, dissection).
— Graft infection (presents months to years later with bacteremia, sepsis, fistula); often Staph aureus, requires graft excision and extra-anatomic bypass.
— Anastomotic pseudoaneurysm.
Board pearl: Any patient with prior aortic graft and GI bleeding has aortoenteric fistula until proven otherwise — even a small "sentinel" bleed warrants urgent CTA and surgical consult. Do not delay for endoscopy alone.
— Hemodynamically unstable patient with suspected ruptured AAA — bypass advanced imaging if surgeon agrees.
— Established rupture on imaging.
— Acute mesenteric or limb ischemia from AAA-related embolism.
— Suspected aortoenteric or aortocaval fistula.
— Symptomatic AAA (new abdominal/back pain, tenderness, embolic events) without overt rupture — repair within days, not weeks.
— Rapid expansion documented on surveillance.
— New finding of AAA ≥5.5 cm (men) or ≥5.0 cm (women).
— AAA approaching threshold (e.g., 4.8–5.4 cm in men) — for surgical planning and pre-op optimization.
— Surveillance imaging schedule established by primary care; refer when criteria met.
— Routinely after open repair for 24–48 h: hemodynamic monitoring, ventilator wean, fluid management, AKI surveillance.
— EVAR often goes to step-down or floor if uncomplicated; ICU for hemodynamic instability, ongoing transfusion, or significant comorbidities.
— Community hospital without vascular surgery → transfer hemodynamically stable patients to tertiary center; for unstable ruptures, balance transfer time against on-site resources (sometimes local damage-control surgery saves more lives than transfer death).
— METS <4 or new cardiac symptoms → stress testing if it changes management.
— Optimize HTN, anemia, glycemic control, smoking cessation (≥4 weeks pre-op ideal).
CCS pearl: In a CCS unstable AAA case, the sequence is: IV access → labs/T&C → MTP activation → vascular surgery consult → OR. CT scan only if hemodynamically stable. Advancing the clock for "one more test" in an unstable patient is the most common CCS error.
— Sudden "tearing" chest or interscapular pain radiating to back; pulse deficits; widened mediastinum on CXR; CTA confirms.
— Type A involves ascending aorta → emergent surgery; Type B distal to left subclavian → medical management with IV beta-blocker, then nitroprusside.
— Can coexist with AAA; key differentiator is rapidity of onset, location, and imaging (true/false lumen with intimal flap vs simple dilation).
— Different anatomy, different repair thresholds (5.5 cm ascending, 6.0 cm descending generally), different etiologies (Marfan, bicuspid valve, syphilis, giant cell arteritis).
— May coexist with AAA — image entire aorta if AAA discovered in a young or syndromic patient.
— Claudication, impotence, diminished femoral pulses — atherosclerotic obstruction, not aneurysm. May coexist with AAA.
— Pulsatile pelvic mass; often discovered in conjunction with AAA. Repair threshold ~3.5 cm common iliac.
— Often incidental; splenic artery aneurysm in pregnancy is high-risk for rupture.
— Fever, elevated WBC, positive blood cultures (often Salmonella, Staph aureus); saccular morphology on CT; treat with prolonged antibiotics + surgical repair (often extra-anatomic bypass).
— Acute aortic syndrome variants; CT distinguishes; management similar to dissection of the same segment.
Key distinction: AAA causes deep, often gnawing abdominal/back pain that can mimic many GI/GU processes. Dissection causes acute, tearing pain that migrates. Both can present with hypotension, but the imaging differentiates: AAA = dilated sac ± retroperitoneal hematoma; dissection = intimal flap with true/false lumen.
— Flank pain radiating to groin, hematuria, often younger patient with prior history.
— Classic Step 3 trap: older smoker with "first kidney stone" → image the aorta. Non-contrast CT can show both — look at the aorta on every renal stone CT.
— LLQ pain, fever, leukocytosis, focal tenderness; CT shows fat stranding around sigmoid.
— Epigastric pain radiating to back, elevated lipase, alcohol/gallstone history.
— Epigastric pain, free air on imaging if perforated.
— "Pain out of proportion to exam," elevated lactate, postprandial pain in chronic form; CTA distinguishes.
— Mechanical features, radicular distribution; AAA back pain is steady, deep, not positional.
— RUQ pain, Murphy sign, abnormal LFTs, US findings.
— Psoas abscess, retroperitoneal hematoma from anticoagulation, retroperitoneal fibrosis (which can be associated with inflammatory AAA).
— Dermatomal pain preceding rash; classic prodrome confounder.
Board pearl: The two non-vascular Step 3 traps for AAA are "first kidney stone in an older smoker" and "musculoskeletal back pain" in someone with risk factors. The discriminator is demographics + a low threshold for bedside US. Any older smoker with new, unexplained abdominal/back pain deserves a look at the aorta.
— Tobacco cessation — single highest-impact intervention; offer counseling + pharmacotherapy at every visit.
— High-intensity statin (atorvastatin 40–80 or rosuvastatin 20–40); LDL goal <70 mg/dL in this ASCVD-equivalent population.
— BP control to <130/80 with ACEi/ARB ± thiazide ± beta-blocker; tailor to comorbidities.
— Aspirin 81 mg daily if coexisting ASCVD (most AAA patients qualify).
— Glycemic control if diabetic (target individualized).
— Lifelong imaging surveillance (CT or duplex US at 1, 6, 12 months, then annually).
— Endocarditis prophylaxis is not routinely indicated for stent grafts (unlike prosthetic heart valves).
— Patient education on signs of endoleak/graft infection: fever, back pain, GI bleeding.
— Less intensive imaging — duplex or CT every 5 years to monitor for anastomotic pseudoaneurysm or new aneurysms (especially thoracic).
— Hernia surveillance at incision.
— Annual influenza, pneumococcal per age/comorbidities, COVID-19, RSV (≥60), zoster — standard preventive care.
— Recommend first-degree relatives ≥55 (men) or ≥65 (women) consider screening US.
Step 3 management: A patient discharged after EVAR needs statin, aspirin, BP control, smoking cessation, lifelong imaging surveillance, lung cancer screening eligibility check, and family member screening recommendation. Forgetting the lung cancer screening or the family screening is a frequent omission.
— 3.0–3.9 cm: every 3 years
— 4.0–4.9 cm: yearly
— 5.0–5.4 cm: every 6 months
— Trigger referral: ≥5.5 cm men, ≥5.0 cm women, growth ≥0.5 cm/6 mo, or symptoms.
— Every 3–6 months for risk factor management while AAA is under surveillance.
— Document BP, lipid panel, HbA1c, smoking status, weight, abdominal exam, distal pulses.
— Open: clinic visit at 2 weeks (wound, pain), 6 weeks (return to activity), then annually.
— EVAR: clinic at 1 month with imaging, then per surveillance protocol; same-day imaging review.
— Activity: routine walking and aerobic exercise encouraged; avoid maximal isometric lifting (Valsalva spikes BP) in large unrepaired aneurysms.
— Smoking cessation: revisit at every visit; document attempts and pharmacotherapy.
— Warning signs: new abdominal/back/flank pain, syncope, leg pain or color change, GI bleeding (especially post-graft), fever — instruct to seek emergency care immediately.
— Driving and travel: generally unrestricted with stable surveillance AAA; large unrepaired aneurysms — discuss individualized.
— Indicated post-open repair if coexisting CAD; improves functional status and survival.
— "Watchful waiting" causes anxiety; acknowledge and counsel; some patients prefer earlier repair for psychological reasons — discuss within shared decision-making but adhere to evidence-based thresholds.
Board pearl: The single most testable surveillance interval: 4.0–4.9 cm = annual ultrasound. The most testable referral trigger: ≥5.5 cm in men, ≥5.0 cm in women, OR growth ≥0.5 cm in 6 months, OR symptoms.
— Both EVAR and open carry real perioperative mortality (1–5%) and significant morbidity — discuss alternatives including continued surveillance and palliative non-operative management.
— Discuss the lifetime imaging burden, reintervention risk (~20% for EVAR over 5 years), and the option of declining surgery.
— Verify decision-making capacity in older patients; involve surrogate per advance directive when appropriate.
— A 78-year-old with multiple comorbidities and a 5.6 cm AAA may have a higher perioperative mortality than annual rupture risk — frame numerically and respect patient values.
— Some patients, especially elderly with poor functional status, have pre-existing wishes against aggressive intervention. Honor DNR/DNI; offer comfort-focused care if repair is not pursued.
— Time-pressured consent in rupture: obtain from patient if capacitated, otherwise from surrogate; emergency exception applies if no surrogate available and delay would cause death.
— Adverse events (graft infection, intraoperative death, retained foreign body) require institutional disclosure and, in many states, reporting per facility policy.
— Open communication with patients/families after complications is both ethical and reduces malpractice risk ("CANDOR" framework).
— Patients discharged post-EVAR must have imaging follow-up arranged before leaving the hospital; failure to schedule first surveillance scan is a documented patient-safety gap leading to missed endoleaks.
— Medication reconciliation at discharge: statin, antiplatelet, antihypertensives, and smoking cessation aids.
— Communicate findings of incidentally discovered AAA to primary care with explicit surveillance plan — "incidentaloma" lost to follow-up is a recurring litigation theme.
— Commercial drivers with unrepaired large AAAs may have licensure restrictions per DOT guidance — counsel and document.
Step 3 management: Whenever a vignette describes an incidental AAA found on imaging done for another reason, the correct next step is document the finding, inform the patient, refer to primary care or vascular surgery with a clear surveillance interval, and ensure communication is closed-loop. "Incidentaloma" mismanagement is a recurring patient-safety stem.
— Men 65–75 ever-smoker: Grade B (one-time US).
— Men 65–75 never-smoker: Grade C (selective).
— Women 65–75 ever-smoker: Grade I.
— Women never-smoker: Grade D.
Board pearl: If a Step 3 vignette gives you "65-year-old man, smoker, here for wellness exam, no prior AAA screening" — the answer is one-time abdominal ultrasound. If it gives you "5.6 cm AAA in a fit 70-year-old man" — the answer is referral for elective repair.
— "67-year-old man with 30 pack-year smoking history presents for Medicare wellness visit. He has no symptoms. What is the most appropriate screening test?"
— Answer: one-time abdominal ultrasound (USPSTF Grade B).
— Distractors: CT angiography (wrong — too much radiation/cost for screening), no screening needed (wrong — he qualifies), screen every year (wrong — one-time).
— "70-year-old man with known 4.3 cm AAA on annual US, stable for 2 years. What is the next step?"
— Answer: continue annual ultrasound surveillance + optimize smoking cessation, statin, BP.
— Distractor: refer for repair (wrong — below threshold and stable).
— "68-year-old woman with 5.1 cm AAA, asymptomatic. Next step?"
— Answer: refer to vascular surgery for elective repair (women threshold is 5.0 cm).
— "72-year-old man with sudden severe abdominal/back pain, BP 80/50, pulsatile abdominal mass. Next step?"
— Answer: emergent vascular surgery consult + OR; if mentioned, two large-bore IVs, T&C, MTP, permissive hypotension. Not "CT scan" if unstable.
— "75-year-old male smoker presents with flank pain and hematuria, treated for 'kidney stone' but recurs."
— Answer: abdominal US/CT to evaluate for AAA — first-time stone in older smoker should not be assumed.
— "Patient 6 months post-open AAA repair presents with melena and fever."
— Answer: CTA for aortoenteric fistula, urgent surgical consult.
— "Patient with known 4.5 cm AAA needs antibiotic for UTI. Which agent should be avoided?"
— Answer: fluoroquinolones (FDA warning).
— "82-year-old frail man with 5.7 cm AAA, oxygen-dependent COPD, CKD 4. Best management?"
— Answer: shared decision-making about risks/benefits of repair vs surveillance/palliation.
Key distinction: Step 3 stems will reward you for choosing counseling, shared decision-making, and longitudinal management over reflexively choosing the most invasive option. Always check the threshold against patient sex and consider competing mortality.
Abdominal aortic aneurysm screening and repair on Step 3: One-time abdominal ultrasound for men 65–75 who have ever smoked (USPSTF Grade B), surveillance by diameter, and elective repair at ≥5.5 cm in men or ≥5.0 cm in women — or sooner for rapid growth or symptoms — layered on top of aggressive smoking cessation, statin, BP control, and antiplatelet therapy because most AAA patients die of MI, not rupture.
Board pearl: If the stem gives you an older male ever-smoker who has never been screened, the answer is one ultrasound — and the right time to think about AAA is before the patient arrives in shock.